JP2021518104A5 - - Google Patents

Info

Publication number
JP2021518104A5
JP2021518104A5 JP2020548722A JP2020548722A JP2021518104A5 JP 2021518104 A5 JP2021518104 A5 JP 2021518104A5 JP 2020548722 A JP2020548722 A JP 2020548722A JP 2020548722 A JP2020548722 A JP 2020548722A JP 2021518104 A5 JP2021518104 A5 JP 2021518104A5
Authority
JP
Japan
Prior art keywords
sequence
seq
region
cdr1
cdr2
Prior art date
Application number
JP2020548722A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019178356A5 (https=
JP2021518104A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/022272 external-priority patent/WO2019178356A1/en
Publication of JP2021518104A publication Critical patent/JP2021518104A/ja
Publication of JP2021518104A5 publication Critical patent/JP2021518104A5/ja
Publication of JPWO2019178356A5 publication Critical patent/JPWO2019178356A5/ja
Priority to JP2024018466A priority Critical patent/JP2024054286A/ja
Withdrawn legal-status Critical Current

Links

JP2020548722A 2018-03-14 2019-03-14 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法 Withdrawn JP2021518104A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024018466A JP2024054286A (ja) 2018-03-14 2024-02-09 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862643040P 2018-03-14 2018-03-14
US62/643,040 2018-03-14
US201862657151P 2018-04-13 2018-04-13
US62/657,151 2018-04-13
PCT/US2019/022272 WO2019178356A1 (en) 2018-03-14 2019-03-14 Engineered cells, t cell immune modulating antibodies and methods for using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024018466A Division JP2024054286A (ja) 2018-03-14 2024-02-09 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2021518104A JP2021518104A (ja) 2021-08-02
JP2021518104A5 true JP2021518104A5 (https=) 2022-04-05
JPWO2019178356A5 JPWO2019178356A5 (https=) 2022-04-05

Family

ID=67908100

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020548722A Withdrawn JP2021518104A (ja) 2018-03-14 2019-03-14 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法
JP2024018466A Pending JP2024054286A (ja) 2018-03-14 2024-02-09 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024018466A Pending JP2024054286A (ja) 2018-03-14 2024-02-09 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法

Country Status (5)

Country Link
US (2) US12258378B2 (https=)
EP (1) EP3765070A4 (https=)
JP (2) JP2021518104A (https=)
AU (2) AU2019235900B2 (https=)
WO (1) WO2019178356A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020113224A2 (en) 2018-11-30 2020-06-04 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptor factories and methods of use thereof
AU2020290579B2 (en) 2019-06-14 2026-02-12 Dana-Farber Cancer Institute, Inc. Antibodies against MUC1 and methods of use thereof
EP4069294A4 (en) * 2019-12-02 2024-07-10 Dana-Farber Cancer Institute, Inc. Antibodies against pd-l1 and methods of use thereof
EP4106802A1 (en) * 2020-02-17 2022-12-28 Miltenyi Biotec B.V. & Co. KG Method for providing personalized cells with chimeric antigen receptors (car) against tumor microenvironment cells
KR20230171465A (ko) 2021-04-22 2023-12-20 아스텔라스세이야쿠 가부시키가이샤 항cldn4-항cd137 이중특이성 항체
WO2023147776A1 (en) * 2022-02-07 2023-08-10 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for enhanced immunotherapies
CN114686592B (zh) * 2022-05-30 2022-09-09 广东忠信生物科技有限公司 一种多类型靶标联合检测的试剂盒及制备方法、使用方法
KR20250099103A (ko) 2022-08-15 2025-07-01 다나-파버 캔서 인스티튜트 인크. Cldn4에 대한 항체 및 이의 사용 방법
CN118252937B (zh) * 2024-04-07 2024-10-22 中山大学 Cxcr4受体的拮抗剂在抗埃博拉病毒感染中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US7750123B2 (en) 2003-11-25 2010-07-06 Dana Farber Cancer Institute, Inc. Antibodies against SARS-CoV and methods of use thereof
WO2006089141A2 (en) 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
WO2007065027A2 (en) 2005-12-02 2007-06-07 Dana Farber Cancer Institute Carbonic anhydrase ix (g250) antibodies and methods of use thereof
EP3524619A1 (en) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
US8962806B2 (en) 2007-12-28 2015-02-24 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2009134962A2 (en) * 2008-04-30 2009-11-05 The Regents Of The University Of California Claudin-4 binding peptides, compositions and methods of use
US9527924B2 (en) 2010-06-02 2016-12-27 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
CA2832389A1 (en) * 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
US9598496B2 (en) 2011-05-09 2017-03-21 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
US8691231B2 (en) * 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
AU2013256010B2 (en) 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
CA2886433C (en) 2012-10-04 2022-01-04 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
MX367668B (es) 2013-03-15 2019-08-30 Dana Farber Cancer Inst Inc Anticuerpos neutralizadores de flavivirus y métodos de uso de los mismos.
AU2015231164B2 (en) 2014-03-19 2020-04-09 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
EP3134111B1 (en) 2014-04-25 2022-06-08 Dana-Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
TWI805109B (zh) * 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
SG11201701529YA (en) * 2014-08-29 2017-03-30 Sorrento Therapeutics Inc Antibody therapeutics that bind oprf and oprl
JP2017531427A (ja) 2014-10-03 2017-10-26 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法
JP6795505B2 (ja) 2014-10-06 2020-12-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法
EP3029067A1 (en) 2014-12-01 2016-06-08 Deutsches Krebsforschungszentrum Use of blocking-reagents for reducing unspecific T cell-activation
BR112017013176A2 (en) * 2014-12-19 2018-05-15 Dana-Farber Cancer Institute Inc. chimeric antigen receptors and methods for using them
KR102668588B1 (ko) 2015-04-08 2024-05-22 다나-파버 캔서 인스티튜트 인크. 인간화된 인플루엔자 모노클로날 항체 및 그의 사용 방법
JO3620B1 (ar) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
EP3349792A1 (en) * 2015-09-14 2018-07-25 Compass Therapeutics LLC Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-

Similar Documents

Publication Publication Date Title
JP2021518104A5 (https=)
Lu et al. Development of therapeutic antibodies for the treatment of diseases
JP2024054286A5 (https=)
JP7573441B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
US11578133B2 (en) Antibodies targeting CD137 and methods of use thereof
US20150197569A1 (en) Anti-kir antibodies, formulations, and uses thereof
JP2018533371A5 (https=)
KR20180133252A (ko) 키메라 항원 및 t 세포 수용체 및 사용 방법
KR20160024391A (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
KR20190028716A (ko) Pd-l1-특이적 항체 및 이를 사용하는 방법
IL295381A (en) bcma-directed chimeric t-cell antigen receptor compounds and methods and uses thereof
JPWO2020077257A5 (https=)
EP4121457A1 (en) Chimeric antigen receptor specific for human cd45rc and uses thereof
JPWO2019178356A5 (https=)
JP7418326B2 (ja) 二重特異性抗体並びにその製造方法及び使用方法
JPWO2022044573A5 (https=)
JPWO2019204462A5 (https=)
CN113811545A (zh) 对btn2具有特异性的抗体及其用途
WO2023046113A1 (zh) 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用
JPWO2020113224A5 (https=)
JPWO2021163389A5 (https=)
US20220363761A1 (en) Multispecific binding moieties comprising novel pd-1 binding domains
JPWO2021035054A5 (https=)
TW202302642A (zh) 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
JPWO2022034524A5 (https=)